Last reviewed · How we verify

Medical Dermatology Specialists — Portfolio Competitive Intelligence Brief

Medical Dermatology Specialists pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levulan® Kerastick® Levulan® Kerastick® marketed Photosensitizing agent Protoporphyrin IX (photodynamic therapy precursor) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Galderma R&D · 1 shared drug class
  2. Novartis · 1 shared drug class
  3. Photocure · 1 shared drug class
  4. QLT Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medical Dermatology Specialists:

Cite this brief

Drug Landscape (2026). Medical Dermatology Specialists — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medical-dermatology-specialists. Accessed 2026-05-16.

Related